




Name	Bor-Sheng Ko	
Current Position	Director, Department of Hematological Oncology, National Taiwan University Cancer Center	
Country	Taiwan	
Major Field	Hematology, Hematopoietic stem cell transplantation, Cell therapy, Pharmacoeconomics	

Educational Background

M.D., School of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. 1988-1995

Ph.D., Institute of Clinical Medicine, College of medicine, National Taiwan University, Taipei, Taiwan. 2003-2011

Professional Experience

Director, Department of Hematological Oncology, National Taiwan University Cancer Center, 2021-

Attending Physician, Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 2002-

Associate Professor, Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. 2019-

Director, Tai-Cheng Cell Therapy Center, National Taiwan University, Taipei, Taiwan, 2021-

Joint Assistant Investigator, Institute of Cellular and Systemic Medicine, National Health Research Institute, Miaoli, Taiwan. 2010-2014

Visiting Research Scholar, Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center and Department of Hematology, Health Science Center of University of Texas-Houston, 2006-2007

Attending physician, Department of Internal Medicine, Far-Eastern Memorial Hospital, Taipei county, Taiwan 2000-2002

Other Experience and Professional Memberships

President, Taiwan Society of Hematology, 2023-

President, Taiwan Society of Pharmaco-economics and Outcome Research (Also Taiwan Chapter, International Society of Pharmaco-economics and Outcome Research), 2018-

President, Taiwan Society of Blood and Marrow Transplantation. 2019-2022

Secretary-General, Taiwan Society of Blood and Marrow Transplantation. 2013-2019

Deputy Secretary-General, Taiwan Society of Hematology, 2013-2014

Member of Scientific Committee, Asia Pacific Blood and Marrow Transplantation (APBMT) group

Member, International Society of Pharmaco-economics and Outcome Research (ISPOR)



Member, European Hematology Association (EHA)

Main Scientific Publications

1. **A Chunking-for-Pooling Strategy for Cytometric Representation Learning for Automatic Hematologic Malignancy Classification.** Li JL, Lin YC, Wang YF, Monaghan SA, **Ko BS (corresponding)***, Lee CC. *IEEE Journal of Biomedical and Health Informatics*. 2022. DOI: 10.1109/JBHI.2022.3175514.
 2. **Stem cell transplant for mantle cell lymphoma in Taiwan.** Wang YH, Hsieh CY, Hsiao LT, Lin TL, Liu YC, Yao M, Tan TD, **Ko BS (corresponding)***. *Sci Rep*. 2022 Apr 5;12(1):5662
 3. **Outcomes of different haploidentical transplantation strategies from the Taiwan Blood and Marrow Transplantation Registry.** Tsai XC, Chen TT, Gau JP, Wang PN, Liu YC, Lien MY, Li CC, Yao M, **Ko BS***. *Cancers (Basel)*. 2022 Feb 21;14(4):1097.
 4. **The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan.** Huang HH, Chen CM, Wang CY, Hsu WW, Chen HM, **Ko BS***, Hsiao FY. *PLoS One*. 2022 Jan 21;17(1):e0261871. doi: 10.1371/journal.pone.0261871.
 5. **Association of Tumor Hydroxyindole O-Methyltransferase and Serum 5-Methoxytryptophan with Long-Term Survival of Hepatocellular Carcinoma.** **Ko BS**, Liang SM, Chang TC, Wu JY, Lee PH, Hsu YJ, Kuo CC, Liou JY, Wu KK. *Cancers (Basel)*. 2021 Oct 22;13(21):5311. doi: 10.3390/cancers13215311.
 6. **A Machine Learning Approach to the Classification of Acute Leukemias and Distinction From Nonneoplastic Cytopenias Using Flow Cytometry Data.**
 7. **Monaghan SA, Li JL, Liu YC, Ko MY, Boyiadzis M, Chang TY, Wang YF, Lee CC, Swerdlow SH, **Ko BS***.** *Am J Clin Pathol*. 2021 Oct 13;aqab148. doi: 10.1093/ajcp/aqab148.
 8. **Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.** Wang YH, Tien FM, Tsai CH, Huang HH, Liu JH, Liao XW, Tang JL, Yao M, **Ko BS***. *Cancer Rep (Hoboken)*. 2021 Jun 30:e1488. doi: 10.1002/cnr.2.1488.
 9. **Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015.** Wang CY, Huang HH, Chen HM, Hsiao FY, **Ko BS***. *Clin Lymphoma Myeloma Leuk*. 2021 Mar 29:S2152-2650(21)00112-9. doi: 10.1016/j.clml.2021.03.010. Online ahead of print.
 10. **Epidemiology, Treatment Patterns, and Survival of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Taiwan, 2006-2015.** **Ko BS**, Chen LJ, Huang HH, Chen HM, Hsiao FY. *Int J Clin Pract*. 2021 Apr 22:e14258. doi: 10.1111/ijcp.14258.
 11. **High rate of invasive fungal infections after non-T cell depleted haploidentical allo-HSCT even under antifungal prophylaxis.** Lien MY, Yeh SP, Gau JP, Wang PN, Li SS, Dai MS, Chen TC, Hsieh PY, Chiou LW, Huang WH, Liu YC; Taiwan Blood and Marrow Transplantation Registry (TBMTR), **Ko BS***. *Bone Marrow Transplant*. 2021 Jul;56(7):1750-1753. doi: 10.1038/s41409-021-01260-7.
 12. **Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review.** Jerry Teng CL, Wang PN, Chen YC, **Ko BS***. *J Microbiol Immunol Infect*. 2021 Jan 13:S1684-1182(21)00014-1.
-



13. **Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B cell lymphoma in Taiwan - a population-based study.** Huang HH, Hsiao FY, Chen HM, Wang CY, **Ko BS***. *Br J Haematol.* 2021 Jan;192(1):110-118.
14. **Frontline treatments in extremely elderly patients with diffuse large B-cell lymphoma: a population-based study in Taiwan, 2010-2015.** Huang HH, **Ko BS(co-1st)**, Chen HM, Chen LJ, Wang CY, Hsiao FY. *Immun Ageing.* 2020 Jun 10;17:17. doi: 10.1186/s12979-020-00188-8.
15. **Expression of Nik-related kinase in smooth muscle cells attenuates vascular inflammation and intimal hyperplasia.** Lu YJ, Jan YJ, **Ko BS (co-1st)**, Liang SM, Chen L, Wu CC, Chin CH, Kuo CC, Yet SF, Liou JY. *Aging (Albany NY).* 2020 Apr 24;12(8):7511-7533.
16. **Adoptive donor immunity protects against resolved HBV reactivation after allo-HSCT in the world's largest retrospective cohort study.** Liu JH, Liao XW, Chen CH, Yao M, Li CC, Lin CT, Tsai CH, Chou WC, Hou HA, Huang SY, Tien HF, Tang JL, **Ko BS***. *Br. J Haematol.* 2019 Jul;186(1):72-85.
17. **ZNF479 downregulates metallothionein-1 expression by regulating ASH2L and DNMT1 in hepatocellular carcinoma.** Wu YJ, **Ko BS (co-1st)**, Liang SM, Lu YJ, Jan YJ, Jiang SS, Shyue SK, Chen L, Liou JY. *Cell Death Dis.* 2019 May 28;10(6):408.
18. **Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan.** **Ko BS**, Chang MC, Chiou TJ, Chang TK, Chen YC, Lin SF, Chang CS, Lu YC, Yeh SP, Chen TY, Hwang WS. *Hematology.* 2019 Dec;24(1):247-254.
19. **Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome.** **Ko BS**, Wang YF, Li JJ, Li CC, Weng PF, Hsu SC, Hou HA, Huang HH, Yao M, Lin CT, Liu CH, Tsai CH, Huang TC, Wu SJ, Huang SY, Chou WC, Tien FM, Lee CC, Tang JL. *EBioMedicine* 2018 Nov;37:91-100.
20. **Subtype-specific epidemiology of lymphoid malignancies in Taiwan compared to Japan and the United States, 2002-2012.** **Ko BS**, Chen LR, Huang HH, Chen HM, Hsiao FY. *Cancer Med.* 2018 Nov;7(11):5820-5831.
21. **Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.** Huang HH, Wen YC, Chen HM, Hsiao FY, **Ko BS***. *Cancer Med.* 2018 Aug;7(8):3582-3591.
22. **Women with diffuse large B cell lymphoma benefit more from rituximab-containing chemotherapy.**
23. **Huang HH, Hsiao FY, Chen LJ, Chen HM, Ko BS*. *J Womens Health (Larchmt).* 2018 Aug;7(8):3582-3591.**
24. **Prognostic significance of 14-3-3 ϵ , aldo-keto reductase family 1 B10 and metallothionein-1 in hepatocellular carcinoma.** Wu CY, Jan YJ, **Ko BS (co-1st)**, Wu YJ, Wu YJ, Liou JY. *Anticancer Res.* 2018 Dec;38(12):6855-6863.